The R&D 15: Top pharma players shell out record $153B for research, and M&A is a prime focus for all
At a time when biotech is still counting its losses as a thaw gradually sets in after the long market winter, pharma has been on …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
